Ribonuclease 1 Enhances Antitumor Immunity against Breast Cancer by Boosting T cell Activation.

In response to compound 1 treatment, in addition to the above-mentioned CD8 + T cell expansion, we observed an increased frequency of NK cells in a near-significant trend (Figure 2 D, clus_3, blue vs. black) and a decreased frequency of pro-tumorigenic M2-like macrophages 41 (clus_8, blue vs. black), which supports tumor suppression due to compound 1 treatment.

also in 39 other papers

RNase1 targets specific subsets of tumor-infiltrating immune cells Consistent with the above data based on the t-SNE-guided stratification (Figure 2 ), a conventional hand-gated strategy ( Figure S3 ) showed that RNase1 increased the frequency of the CD4 + T cell subset by greater than two-fold and the CD8 + T cell subset with a trend toward significance (Figure 3 A and 3 B).

also in 499 other papers